Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 1;49(12):2157-2160.
doi: 10.1097/CCM.0000000000005162.

Glucocorticoid-Glucocorticoid Receptor Response to Severe Acute Respiratory Syndrome Coronavirus 2

Djillali Annane  1   2   3   4   5   6 , Véronique Godot  1   2   3   4   5   6
Affiliations

Glucocorticoid-Glucocorticoid Receptor Response to Severe Acute Respiratory Syndrome Coronavirus 2

Djillali Annane et al. Crit Care Med. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. Annane’s institution received funding from the French Government, Programme d’Investissements d’Avenir (ANR-18-RHUS-0004). Dr. Godot has disclosed that she does not have any potential conflicts of interest.

Figures

Figure 1.
Figure 1.
Schematic summary of current knowledge about glucocorticoid-induced leucine zipper (GILZ) protein in the setting of viral or bacterial sepsis. ARDS = acute respiratory distress syndrome, COVID-19 = coronavirus disease 2019, GCR-α = glucocorticoid receptor-α, mRNA = messenger RNA.
See this image and copyright information in PMC

References

    1. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395:473–475 - PMC - PubMed
    1. Zhang W, Zhao Y, Zhang F, et al. . The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The perspectives of clinical immunologists from China. Clin Immunol. 2020; 214:108393. - PMC - PubMed
    1. RECOVERY Collaborative Group: Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384:693–704 - PMC - PubMed
    1. Angus DC, Derde L, Al-Beidh F, et al. ; Writing Committee for the REMAP-CAP Investigators: Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020; 324:1317–1329 - PMC - PubMed
    1. Dequin PF, Heming N, Meziani F, et al. ; CAPE COVID Trial Group and the CRICS-TriGGERSep Network: Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: A randomized clinical trial. JAMA. 2020; 324:1298–1306 - PMC - PubMed

Publication types

Substances